Photocure (DB:PHS) - Prezzo delle azioni, notizie e analisi

PHS Panoramica delle azioni

PHS analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	3/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 87.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 94.94% all'anno

È diventato redditizio quest'anno

Analisi del rischio

Le azioni sono altamente illiquide

Photocure ASA Concorrenti

Pierrel

DB:2FJ0

€92.8m

PharmaSGP Holding

XTRA:PSG

€287.8m

MPH Health Care

DB:93M1

€105.3m

Dermapharm Holding

XTRA:DMP

€2.0b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Photocure
Prezzi storici delle azioni
Prezzo attuale dell'azione	NOK 4.41
Massimo di 52 settimane	NOK 4.84
Minimo di 52 settimane	NOK 4.28
Beta	0.99
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	-62.72%
Variazione a 5 anni	n/a
Variazione dall'IPO	-25.88%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	PHS	DE Pharmaceuticals	DE Mercato
7D	0%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato PHS rispetto al settore German Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di PHS rispetto al mercato German.

Volatilità dei prezzi

Is PHS's price volatile compared to industry and market?
PHS volatility
PHS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di PHS è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di PHS nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, insieme alle sue controllate, si occupa di ricerca, sviluppo, produzione, distribuzione, commercializzazione e vendita di prodotti farmaceutici nei Paesi nordici, in Germania, Francia, Austria, Regno Unito, BeNeLux, Italia, altri Paesi europei, Canada e Stati Uniti. Opera attraverso i segmenti Commercial Franchise e Development Portfolio. L'azienda offre Hexvix/Cysview per il rilevamento e la gestione del tumore alla vescica.

Photocure ASA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Photocure con la sua capitalizzazione di mercato?
PHS statistiche fondamentali
Capitalizzazione di mercato	€117.53m
Guadagni(TTM)	€1.22m
Ricavi(TTM)	€45.18m

96.6x

Rapporto P/E

2.6x

Rapporto P/S

PHS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PHS Conto economico (TTM)
Ricavi	NOK 526.25m
Costo del fatturato	NOK 29.11m
Profitto lordo	NOK 497.15m
Altre spese	NOK 482.98m
Guadagni	NOK 14.16m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.52
Margine lordo	94.47%
Margine di profitto netto	2.69%
Rapporto debito/patrimonio netto	0%

Come si è comportato PHS nel lungo periodo?

Vedi performance storica e confronto

PHS Panoramica delle azioni

Premi

Analisi del rischio

Photocure ASA Concorrenti

DB:2FJ0

€92.8m

XTRA:PSG

€287.8m

DB:93M1

€105.3m

XTRA:DMP

€2.0b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Recent updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.81 loss in 1Q 2022)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

New 90-day high: €10.40

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

New 90-day high: €9.02

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Photocure ASA Riepilogo dei fondamenti

96.6x

2.6x

Guadagni e ricavi